Article
Oncology
Alan L. Ho, Irene Brana, Robert Haddad, Jessica Bauman, Keith Bible, Sjoukje Oosting, Deborah J. Wong, Myung-Ju Ahn, Valentina Boni, Caroline Even, Jerome Fayette, Maria Jose Flor, Kevin Harrington, David S. Hong, Sung-Bae Kim, Lisa Licitra, Ioanna Nixon, Nabil F. Saba, Stephan Hackenberg, Pol Specenier, Francis Worden, Binaifer Balsara, Mollie Leoni, Bridget Martell, Catherine Scholz, Antonio Gualberto
Summary: This study evaluated the efficacy of Tipifarnib in patients with HRAS mutations in R/M HNSCC, showing an objective response rate of 55% in high-VAF HNSCC patients. Tipifarnib demonstrated longer progression-free survival and overall survival compared to previous therapies, with the most frequent treatment-emergent adverse events being anemia and lymphopenia.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Nabil F. Saba, Conor E. Steuer, Asari Ekpenyong, Ashley McCook-Veal, Kelly Magliocca, Mihir Patel, Nicole C. Schmitt, William Stokes, James E. Bates, Soumon Rudra, Jill Remick, Mark McDonald, Marin Abousaud, Aik Choon Tan, Muhammad Zaki Hidayatullah Fadlullah, Ritu Chaudhary, Jameel Muzaffar, Kedar Kirtane, Yuan Liu, Georgia Z. Chen, Dong M. Shin, Yong Teng, Christine H. Chung
Summary: PD-1 therapy is standard treatment for recurrent metastatic head and neck squamous cell carcinoma. The combination of Pembrolizumab and Cabozantinib shows promising clinical activity. Further research is needed.
Article
Medicine, General & Internal
Anna Lee, Robbie Woods, Amgad Mahfouz, Sarin Kitpanit, Olivia Cartano, Nader Mohamed, Irini Youssef, Kathryn Marqueen, Kevin Sine, Dennis Mah, Brian Neal, Kaveh Zakeri, Jung J. Kang, Nadeem Riaz, Yao Yu, Sean M. McBride, Linda D. Chen, C. Jillian Tsai, Daphna Y. Gelblum, Robert H. Press, Loren S. Michel, Eric J. Sherman, David Pfister, Lara A. Dunn, Alan L. Ho, James Fetten, Richard J. Wong, Jay O. Boyle, Bhuvanesh Singh, Jennifer R. Cracchiolo, Ian Ganly, Marc A. Cohen, Nancy Y. Lee
Summary: This retrospective cohort study evaluated the outcomes and toxic effects of proton therapy reirradiation (PT-ReRT) in patients with head and neck squamous cell carcinoma. The study found that PT-ReRT can improve survival rates, but patients are still at risk of early and late complications.
Article
Oncology
Senthamil R. Selvan, Jennifer A. Brichetti, Denise B. Thurber, Gregory M. Botting, Greg P. Bertenshaw
Summary: This study suggests that nutrient modification may enhance response to cetuximab in SCC patients, and dynamic biomarkers can be used to predict patient response to the drug. Further studies in more complex samples including patient-derived tumor tissues are needed to validate these findings.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
(2021)
Article
Oncology
Amanda E. Yung, Gareth Crouch, Alexander H. R. Varey, Serigne Lo, Michael S. Elliott, Jenny Lee, Robert Rawson, Ruta Gupta, Angela M. Hong, Jonathan R. Clark, Sydney Ch'ng
Summary: More than 60% of patients treated surgically for pT3/4 HNcSCC were alive and free of disease at 5 years posttreatment. High-risk features such as margin involvement and having had previous treatment (radiotherapy/surgery) should be used to guide adjuvant therapy.
ANNALS OF SURGICAL ONCOLOGY
(2022)
Article
Oncology
Kevin J. Harrington, Barbara Burtness, Richard Greil, Denis Soulieres, Makoto Tahara, Gilberto de Castro Jr, Amanda Psyrri, Irene Brana, Neus Baste, Prakash Neupane, Ase Bratland, Thorsten Fuereder, Brett G. M. Hughes, Ricard Mesia, Nuttapong Ngamphaiboon, Tamara Rordorf, Wan Zamaniah Wan Ishak, Jianxin Lin, Burak Gumuscu, Ramona F. Swaby, Danny Rischin
Summary: The study presents a post hoc analysis of the long-term efficacy and progression-free survival in recurrent/metastatic head and neck squamous cell carcinoma patients treated with pembrolizumab and pembrolizumab-chemotherapy as next-line therapy. The results demonstrate favorable clinical efficacy and progression-free survival with pembrolizumab and pembrolizumab-chemotherapy in patients with programmed death ligand 1 (PD-L1) combined positive score (CPS) >= 20, CPS >= 1, and total populations. Subsequent treatments after pembrolizumab-based therapy also showed good efficacy.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Medicine, Research & Experimental
Saba Shafi, Thazin Nwe Aung, Vasiliki Xirou, Niki Gavrielatou, Ioannis A. Vathiotis, Aileen Fernandez, Myrto Moutafi, Vesal Yaghoobi, Roy S. Herbst, Linda N. Liu, Sol Langermann, David L. Rimm
Summary: The study assesses the expression of immune system modulator Siglec-15 in different types of cancer and finds increased expression in both tumor and immune cells. The results suggest Siglec-15 as a potential target for immunotherapy and provide insights for future clinical trials and companion diagnostic tests.
LABORATORY INVESTIGATION
(2022)
Article
Oncology
Alan L. Ho
Summary: This article discusses the application of immune checkpoint inhibitors in the treatment of head and neck squamous cell carcinoma, specifically the use of pembrolizumab in first-line therapy. Through a case study, the practical application of the KEYNOTE-048 study results in clinical practice is highlighted.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Biotechnology & Applied Microbiology
Ming Zhang, Ganping Wang, Zhikun Ma, Gan Xiong, Wenjin Wang, Zhengxian Huang, Yuehan Wan, Xiuyun Xu, Rosalie G. Hoyle, Chen Yi, Jinsong Hou, Xiqiang Liu, Demeng Chen, Jiong Li, Cheng Wang
Summary: This study demonstrates that BET inhibition enhances CD8+ T cell-based antitumor immunity in HNSCC by promoting the expression of MHC class I molecules. It also shows that the combination of BET inhibition with anti-PD-1 antibody treatment significantly enhances the antitumor response in HNSCC.
Article
Oncology
Brian J. Park, Austin K. Mattox, Daniel Clayburgh, Mihir Patel, R. Bryan Bell, Bevan Yueh, Rom Leidner, Hong Xiao, Marcus Couey, Shiting Li, Tingting Qin, Maureen A. Sartor, Belinda Cairns, Tracy MacDonough, Kyle Halliwill, Daniel Deschler, Derrick T. Lin, William C. Faquin, Peter M. Sadow, Sara Pai
Summary: PD-L1 testing is important for decision-making in HNSCC treatment. Chemoradiation therapy has a significant impact on PD-L1 expression, especially when using a cut-off of CPS >= 20 and >= 50. Oral cavity cancer shows higher discordance rates in local and regional recurrence, suggesting the need for repeat biopsy.
Article
Oncology
Tien-Hua Chen, Yi-Ying Pan, Tsung-Lun Lee, Ling-Wei Wang, Shyh-Kuan Tai, Pen-Yuan Chu, Wen-Liang Lo, Cheng-Hsien Wu, Muh-Hwa Yang, Peter Mu-Hsin Chang
Summary: This study investigated the treatment outcomes and clinical factors associated with better survival outcomes in patients with locally recurrent and distant metastatic squamous cell carcinoma of the head and neck who were treated with a cetuximab-containing regimen. The results showed that patients with local recurrence had longer overall survival and progression-free survival compared to those with distant metastasis, and there were more patients with oral cavity cancer and early recurrence within 6 months after radiation therapy in the local recurrence group.
Article
Otorhinolaryngology
Shuo Yang, Zhi-Jun Yuan, Yue-Hong Zhu, Xue Chen, Wei Wang
Summary: The study revealed that lncRNA PVT1 decreases the sensitivity of HNSCC cells to cetuximab by enhancing methylation-mediated inhibition of miR-124-3p, providing a new insight into the cetuximab chemoresistance of HNSCC.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
(2021)
Review
Oncology
Nanami L. Miyazaki, Aki Furusawa, Peter L. Choyke, Hisataka Kobayashi
Summary: RM-1929 NIR-PIT is an emerging treatment that has been shown to be well-tolerated and clinically meaningful for patients with unresectable and/or recurrent head and neck squamous cell carcinoma.
Article
Cell Biology
Erliang Guo, Xionghui Mao, Xueying Wang, Lunhua Guo, Changming An, Cong Zhang, Kaibin Song, Guohui Wang, Chunbin Duan, Xiwei Zhang, Xianguang Yang, Zhennan Yuan, Ji Sun, Xiaomei Li, Weiwei Yang, Hongxue Meng, Susheng Miao
Summary: High expression of ANLN is associated with poor prognosis in HNSCC patients. The two major splice variants of ANLN, ANLN-201 and ANLN-210, are highly expressed in HNSCC tissues and cell lines. ANLN promotes tumor growth and invasion in HNSCC by interacting with c-Myc and hnRNPC in different mechanisms.
CELL DEATH & DISEASE
(2021)
Article
Otorhinolaryngology
Nicole L. Michmerhuizen, Megan L. Ludwig, Andrew C. Birkeland, Sai Nimmagadda, Jingyi Zhai, Jiayu Wang, Brittany M. Jewell, Dylan Genouw, Lindsay Remer, Daniel Kim, Susan K. Foltin, Apurva Bhangale, Aditi Kulkarni, Carol R. Bradford, Paul L. Swiecicki, Thomas E. Carey, Hui Jiang, J. Chad Brenner
Summary: This study identified novel synergistic combinations of EGFR inhibitors with other advanced inhibitors through a high throughput drug screen, showing promising cell activity in resistant models.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
(2022)
Article
Oncology
Elisabetta Schiavello, Veronica Biassoni, Giovanna Gattuso, Marta Podda, Stefano Chiaravalli, Francesco Barretta, Manila Antonelli, Loris De Cecco, Emilia Pecori, Lorenza Gandola, Maura Massimino
Summary: This is a small series of homogeneously-treated DMG patients with H3K27M mutation. The treatment approach is similar to DIPG and the results obtained are comparable with those of DIPG patients. Therefore, these DMG patients should be included in registries and protocols of DIPG.
Article
Oncology
Giancarla Bernardo, Valentino Le Noci, Emerenziana Ottaviano, Loris De Cecco, Chiara Camisaschi, Simone Guglielmetti, Martina Di Modica, Giorgio Gargari, Francesca Bianchi, Serena Indino, Patrizia Sartori, Elisa Borghi, Michele Sommariva, Elda Tagliabue, Tiziana Triulzi, Lucia Sfondrini
Summary: This study highlights the significant influence of mammary tumor microbiota on local immune status and the relevance of its treatment with antibiotics, in combination with breast cancer therapies.
Review
Oncology
Elena Colombo, Arianna Ottini, Lisa Licitra
Summary: The purpose of this review is to address the treatment options for patients with slowly progressive and/or symptomatic oligometastatic radioactive iodine refractory (RAIR) differentiated thyroid carcinomas (DTCs). The recent literature on this topic has not been extensively reviewed in previous publications, and this review aims to fill the gaps in knowledge.
CURRENT OPINION IN ONCOLOGY
(2023)
Article
Oncology
Laura D. Locati, Elena Colombo, Marek Dedecjus, Christelle de la Fouchardiere, Ward Sents, Massimo Bongiovanni, Romana Netea-Maier
Summary: Anaplastic thyroid carcinoma (ATC) is a rare and deadly cancer, and there are challenges in prescribing novel treatments in Europe as they haven't been licensed for ATC yet. Patients manage to receive these drugs through alternative ways. An investigation showed disparities in access to new treatments, and it emphasized the urgent need for access to cutting-edge therapies and the feasibility of clinical trials.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Anna Koot, Paula Soares, Eyal Robenshtok, Laura D. Locati, Christelle de la Fouchardiere, Markus Luster, Massimo Bongiovanni, Rosella Hermens, Petronella Ottevanger, Frans Geenen, Beate Bartes, Harald Rimmele, Cosimo Durante, Els Nieveen-van Dijkum, Peep Stalmeier, Marek Dedecjus, Romana Netea-Maier
Summary: The incidence of differentiated thyroid cancer (DTC) is increasing globally, mainly due to the detection of micro papillary thyroid carcinomas (microPTCs), which often lead to overtreatment without improvement in mortality rate. Less aggressive approaches, such as active surveillance or minimally invasive treatments (MIT), have been suggested as alternatives. Patient participation in decision-making process is crucial. The Endocrine Task Force of the EORTC aims to establish consensus and provide practical suggestions for implementing shared decision making (SDM) based on scientific evidence and patients' needs.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Endocrinology & Metabolism
Giovanni Centonze, Patrick Maisonneuve, Natalie Prinzi, Sara Pusceddu, Luca Albarello, Eleonora Pisa, Massimo Barberis, Alessandro Vanoli, Paola Spaggiari, Paola Bossi, Laura Cattaneo, Giovanna Sabella, Enrico Solcia, Stefano La Rosa, Federica Grillo, Giovanna Tagliabue, Aldo Scarpa, Mauro Papotti, Marco Volante, Alessandro Mangogna, Alessandro Del Gobbo, Stefano Ferrero, Luigi Rolli, Elisa Roca, Luisa Bercich, Mauro Benvenuti, Luca Messerini, Frediano Inzani, Giancarlo Pruneri, Adele Busico, Federica Perrone, Elena Tamborini, Alessio Pellegrinelli, Ketevani Kankava, Alfredo Berruti, Ugo Pastorino, Nicola Fazio, Fausto Sessa, Carlo Capella, Guido Rindi, Massimo Milione
Summary: This study analyzed a large series of neuroendocrine carcinomas (NECs) to validate previously identified prognostic factors and determine if additional parameters could be isolated. The most relevant predictors for prognosis were Ki-67 index, morphology, stage, and site. However, morphology was not a significant factor when Ki-67 was greater than or equal to 55%.
NEUROENDOCRINOLOGY
(2023)
Article
Oncology
Stefano Cavalieri, Imperia Nuzzolese, Arianna Ottini, Cristiana Bergamini, Carlo Resteghini, Elena Colombo, Salvatore Alfieri, Pasquale Quattrone, Giuseppina Calareso, Nicola Alessandro Iacovelli, Marzia Franceschini, Lisa Licitra
Summary: This study aimed to describe the natural history of AR-positive recurrent/metastatic (R/M) salivary gland carcinoma (SGC) patients based on HER2 amplification status. The results showed that HER2 amplification was associated with a higher risk of disease recurrence and death from R/M disease compared to HER2-negative patients, as well as a non-statistically significant higher prevalence of CNS metastases.
FRONTIERS IN ONCOLOGY
(2023)
Review
Biology
Amelia Barcellini, Alexandra Charalampopoulou, Loris De Cecco, Andrei Fodor, Emanuela Rabaiotti, Giorgio Candotti, Simona Secondino, Angelica Facoetti, Laura Deborah Locati, Sandro Pignata, Ester Orlandi, Giorgia Mangili
Summary: Radiotherapy is increasingly being used in combination with surgery, chemotherapy, and novel drugs to treat ovarian cancer. This review aims to summarize the current understanding of the radiosensitivity and radioresistance of ovarian cancer, which is the deadliest gynecological cancer worldwide. Understanding the mechanisms of radiosensitivity and identifying potential biomarkers of radioresistance could be crucial in guiding clinical decision-making, considering the high rate of recurrence in and out of the radiotherapy fields, especially in the era of personalized oncology.
Article
Oncology
Luca Forlani, Loris De Cecco, Vittorio Simeon, Biagio Paolini, Marina Bagnoli, Sabrina Chiara Cecere, Anna Spina, Eleonora Citeroni, Eliana Bignotti, Domenica Lorusso, Laura Arenare, Daniela Russo, Carmine De Angelis, Laura Ardighieri, Giosue Scognamiglio, Michele Del Sesto, Germana Tognon, Daniela Califano, Clorinda Schettino, Paolo Chiodini, Francesco Perrone, Delia Mezzanzanica, Sandro Pignata, Antonella Tomassetti
Summary: The membrane expression of EGFR can serve as a prognostic biomarker in ovarian cancer patients and is associated with the efficacy of anti-angiogenic therapy.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2023)
Editorial Material
Oncology
Mario A. Hermsen, Paolo Bossi, Alessandro Franchi, Matt Lechner
Article
Oncology
Elena Colombo, Cristina Gurizzan, Arianna Ottini, Francesca Caspani, Cristiana Bergamini, Laura D. D. Locati, Chiara Marchiselli, Andrea Alberti, Luigi Lorini, Lisa F. F. Licitra, Paolo Bossi, Carlo Resteghini
Summary: Basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC) are common human cancers with various risk factors. Current treatments include localized therapies and systemic therapies such as Sonic Hedgehog inhibitors and PD-1 checkpoint inhibitors. However, there is a lack of specific recommendations for advanced synchronous BCC/cSCC not amenable to local treatments. In this article, two elderly patients with synBCC/cSCC of the head and neck had successful combined therapy with cemiplimab and sonidegib, achieving significant clinical benefit without major adverse events. Further exploration of the synergistic effects of targeted therapies and immunotherapy is warranted.
FRONTIERS IN ONCOLOGY
(2023)
Review
Oncology
Kara K. Palmer, Adam Pennell, Bryan Terlizzi, Michael A. Nunu, David F. Stodden, Leah E. Robinson, Alice Bergamini, Sandro Pignata, Ester Orlandi, Giorgia Mangili, David A. Gewirtz
Summary: The management of high-risk gestational trophoblastic neoplasia requires a multimodality treatment that may include radiotherapy. There is little consensus on the indication and role of radiotherapy for extra-central nervous system localizations. Radiotherapy can have a hemostatic role, but the high rate of necrosis requires attention to fractionation schedules and radiation type.
Article
Oncology
Stefano Cavalieri, Viviana Vitolo, Amelia Barcellini, Sara Ronchi, Angelica Facoetti, Chiara Campo, Catherine Klersy, Silvia Molinelli, Francesco Agustoni, Virginia Valeria Ferretti, Annalisa De Silvestri, Marco Platania, Michele Del Vecchio, Marco Durante, Alexander Helm, Claudia Fournier, Filippo de Braud, Paolo Pedrazzoli, Ester Orlandi, Lisa Licitra
Summary: ICONIC is a phase II clinical trial that aims to assess the feasibility and clinical activity of combining carbon ion radiotherapy with immune checkpoint inhibitors in cancer patients. This study will provide controlled data regarding the safety of this novel therapeutic combination, as no previous clinical trials have evaluated it.
Letter
Surgery
Armando G. Licata, Chiara M. Ciniselli, Luca Sorrentino, Arianna Micali, Maria Grazia Daidone, Marcello Guaglio, Manuela Gariboldi, Paolo Verderio, Loris De Cecco, Maurizio Cosimelli
BRITISH JOURNAL OF SURGERY
(2023)
Article
Endocrinology & Metabolism
Jaume Capdevila, Desiree' Deandreis, Cosimo Durante, Sophie Leboulleux, Markus Luster, Romana Netea-Maier, Kate Newbold, Susanne Singer, Gerasimos P. Sykiotis, Beate Bartes, Kate Farnell, Laura Deborah Locati
Summary: It is essential to provide guidance for the management of RAI-R DTC patients with systemic therapies, and especially lenvatinib, since compliance and adherence to treatment are fundamental to achieve the best outcomes. The therapeutic landscape in RAI-R DTC is evolving, with new targeted therapies, immunotherapy, etc., lenvatinib is expected to remain a first-line treatment and mainstay of therapy for several years in the vast majority of patients and settings.
EUROPEAN THYROID JOURNAL
(2023)